Blue­bird's $175M loan; Spyre re­veals sec­ond pri­vate place­ment

Plus, news about Fen­nec, As­traZeneca, Bio­mX and Pfiz­er:

Blue­bird bio gets more mon­ey: The gene ther­a­py mak­er inked a five-year, $175 mil­lion loan fa­cil­i­ty with Her­cules Cap­i­tal, start­ing with $75 mil­lion in the first batch. Blue­bird is com­mer­cial­iz­ing its three new­ly ap­proved gene ther­a­pies. — Kyle LaHu­cik

Spyre Ther­a­peu­tics rais­es an­oth­er $180M: Three months af­ter an­nounc­ing a $180 mil­lion pri­vate place­ment, the Boston-area IBD drug­mak­er is back again for the same amount. — Kyle LaHu­cik

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER